ORAMED PHARMACEUTICALS INC. (ORMP) Return on equity 2016–2025
ORAMED PHARMACEUTICALS INC. (ORMP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
32.1%FY2025 · since FY2016: -41.9% → 32.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 32.1% | — |
| FY2023 | 3.1% | +27.2 pp |
| FY2022 | -24.1% | -4.2 pp |
| FY2021 | -19.9% | +15.2 pp |
| FY2020 | -35.0% | +39.0 pp |
| FY2019 | -74.0% | -33.1 pp |
| FY2018 | -40.9% | +13.6 pp |
| FY2017 | -54.5% | -12.6 pp |
| FY2016 | -41.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice